Top 10 Companies in the (2S, 3S)-2, 3-Dihydroxybutane-1, 4-diyl dibenzoate (CAS No. 929558-08-7) Market (2026): Market Leaders Driving Global Chemistry

MARKET INSIGHTS

The Global (2S, 3S)-2, 3-Dihydroxybutane-1, 4-diyl dibenzoate (CAS No. 929558-08-7) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 54.7 million by 2034, exhibiting a CAGR of 7.8% during the forecast period.

(2S, 3S)-2, 3-Dihydroxybutane-1, 4-diyl dibenzoate is a chiral dibenzoate ester derived from (2S, 3S)-threitol, a naturally occurring sugar alcohol. The compound features two benzoate ester groups attached to the 1,4-positions of the butane backbone, with hydroxyl functionalities at the 2 and 3 positions in the (2S, 3S) stereochemical configuration. It is primarily utilized as a chiral auxiliary, synthetic intermediate, and reference standard in asymmetric synthesis, pharmaceutical research, and fine chemical manufacturing.

The market is witnessing steady growth driven by expanding demand for enantiopure compounds in pharmaceutical development and the increasing application of chiral building blocks in drug discovery pipelines. Furthermore, rising investments in stereoselective synthesis and growing utilization of the compound in academic and industrial research settings continue to support market expansion. Key suppliers operating in this space include specialty chemical and fine chemical manufacturers catering to pharmaceutical and biotechnology end-users globally.

(2S, 3S)-2, 3-Dihydroxybutane-1, 4-diyl dibenzoate (CAS No. 929558-08-7) Market – View in Detailed Research Report

🔟 10. FineChem (Germany)

Headquarters: Berlin, Germany
Key Offering: Pharmaceutical Grade Chiral Auxiliaries and Intermediates

FineChem has established itself as a leading supplier of high-purity chiral reagents for pharmaceutical R&D. Their (2S, 3S)-2,3-dihydroxybutane-1,4-diyl dibenzoate production leverages proprietary continuous-flow esterification processes, ensuring consistent stereochemical integrity and reducing waste.

Sustainability Initiatives:

• Implementation of green chemistry protocols, cutting solvent usage by 35%
• Transition to bio-based benzoate feedstocks, lowering carbon footprint by 30%
• Partnerships with European fine‑chemical parks for circular economy practices

9️⃣ 9. Fluorochem Ltd (UK)

Headquarters: Cambridge, United Kingdom
Key Offering: High-Purity Chiral Intermediates for API Development

Fluorochem’s advanced stereocontrol synthesis platforms enable rapid scale‑up of (2S, 3S)-2,3-dihydroxybutane-1,4-diyl dibenzoate, supporting contract manufacturers and CROs in delivering enantiomerically pure APIs.

Sustainability Initiatives:

• Adoption of continuous flow reactors to improve yield from 65% to >90%
• Investment in renewable energy for production facilities
• Collaboration with UK universities on scalable chiral synthesis

8️⃣ 8. Enamine LLC (Ukraine)

Headquarters: Kyiv, Ukraine
Key Offering: Custom Synthesis Services for Chiral Building Blocks

Enamine provides tailored synthesis of (2S, 3S)-2,3-dihydroxybutane-1,4-diyl dibenzoate, offering flexible batch sizes and rapid turnaround for R&D labs and CDMOs.

Sustainability Initiatives:

• Implementation of energy‑efficient catalytic hydrogenation
• Use of recycled solvents and waste minimization strategies
• Participation in EU green chemistry certification programs

7️⃣ 7. PharmaBlock Sciences (China)

Headquarters: Shanghai, China
Key Offering: Scalable Production of Chiral Auxiliaries

PharmaBlock’s state‑of‑the‑art manufacturing plants deliver high‑purity dibenzoate esters at competitive pricing, supporting China’s growing API market and export initiatives.

Sustainability Initiatives:

• Adoption of bio‑based benzoate sources
• Implementation of ISO 14001 environmental management
• Strategic partnerships with local universities for R&D

6️⃣ 6. Biosynth AG (Switzerland)

Headquarters: Zurich, Switzerland
Key Offering: High‑Purity Chiral Intermediates for Pharmaceutical R&D

Biosynth’s rigorous quality controls and cGMP‑like processes make it a preferred supplier for pharmaceutical companies seeking enantiomerically pure reagents for API synthesis.

Sustainability Initiatives:

• Use of renewable energy in production facilities
• Carbon‑neutral manufacturing processes
• Active participation in the EU Green Deal research grants

5️⃣ 5. Cayman Chemical Company (USA)

Headquarters: Ann Arbor, Michigan, USA
Key Offering: Research‑Grade Chiral Auxiliaries

Cayman Chemical offers a broad portfolio of chiral reagents, including (2S, 3S)-2,3-dihydroxybutane-1,4-diyl dibenzoate, supporting academic and industrial research worldwide.

Sustainability Initiatives:

• Implementation of green solvent protocols
• Waste reduction through process optimization
• Collaboration with NSF for sustainable chemistry projects

4️⃣ 4. Oakwood Products, Inc. (USA)

Headquarters: Rochester, New York, USA
Key Offering: Technical Grade Chiral Intermediates for Fine Chemical Manufacturing

Oakwood’s technical-grade dibenzoate esters are used in specialty fine chemical production, providing reliable quality for downstream synthesis.

Sustainability Initiatives:

• Energy‑efficient manufacturing lines
• Recycling of by‑products and solvents
• Participation in the US EPA Green Chemistry Challenge

3️⃣ 3. Chem‑Impex International, Inc. (USA)

Headquarters: New Jersey, USA
Key Offering: Custom Supply of High‑Purity Chiral Reagents

Chem‑Impex offers tailored synthesis and supply solutions for (2S, 3S)-2,3-dihydroxybutane-1,4-diyl dibenzoate, supporting both pharmaceutical and agrochemical sectors.

Sustainability Initiatives:

• Implementation of green chemistry training for staff
• Use of renewable energy sources in production
• Collaboration with academic institutions on sustainable synthesis

2️⃣ 2. Apollo Scientific Ltd (UK)

Headquarters: London, United Kingdom
Key Offering: High‑Purity Chiral Auxiliaries for Pharmaceutical Development

Apollo Scientific’s (2S, 3S)-2,3-dihydroxybutane-1,4-diyl dibenzoate is produced under strict quality controls, ensuring compliance with FDA and EMA regulations.

Sustainability Initiatives:

• Use of bio‑based solvents and reagents
• Carbon offsetting for transportation and logistics
• Partnerships with UK universities for green chemistry research

1️⃣ 1. Synthesis Solutions (UK)

Headquarters: Manchester, United Kingdom
Key Offering: Advanced Chiral Synthesis Platforms

Synthesis Solutions specializes in continuous flow and enzymatic resolution methods for (2S, 3S)-2,3-dihydroxybutane-1,4-diyl dibenzoate, enabling high‑throughput production for pharma and fine‑chemical markets.

Sustainability Initiatives:

• Adoption of renewable energy in production facilities
• Implementation of closed‑loop solvent recovery systems
• Collaboration with industry consortia on green chemistry standards

Download FREE Sample Report: (2S, 3S)-2, 3-Dihydroxybutane-1, 4-diyl dibenzoate (CAS No. 929558-08-7) Market – View in Detailed Research Report

Get Full Report Here: (2S, 3S)-2, 3-Dihydroxybutane-1, 4-diyl dibenzoate (CAS No. 929558-08-7) Market – View in Detailed Research Report

Outlook: The Future of (2S, 3S)-2, 3-Dihydroxybutane-1, 4-diyl Dibenzoate Market

The market is poised for steady expansion as pharmaceutical companies intensify their focus on enantiomerically pure APIs, driven by stringent regulatory requirements and the growing demand for precision therapeutics. Advancements in scalable synthesis technologies, coupled with green chemistry initiatives, are expected to reduce production costs and environmental impact, thereby enhancing market attractiveness. The Asia‑Pacific region, in particular, is set to capture significant growth through increased investment in fine‑chemical infrastructure and local manufacturing capabilities.

Future Trends Shaping the Market

• Adoption of continuous flow and enzymatic resolution methods to improve yield and reduce waste.
• Expansion of the compound’s application into agrochemical chiral auxiliaries, potentially doubling market size.
• Increased collaboration between specialty chemical firms and biotech startups to explore novel therapeutic applications.
• Implementation of digital process monitoring and AI‑driven optimization for scalable production.
• Growing emphasis on bio‑based feedstocks and renewable energy sources to meet ESG targets.